How I treat myelodysplastic syndromes Volume 29, issue 5, 2023-09-01


  • Figure 1


1 Institut de recherche Saint-Louis (IRSL), université Paris Cité, Paris, France
2 Service d’hématologie clinique, hôpital Saint-Louis, AP-HP, Paris, France
3 Inserm UMR 1160, Paris, France
4 Inserm U944/CNRS UMR7212, Paris, France
* Tirés-à-part : M. Sébert <marie.sebert@aphp.fr>
Liens d'intérêts : les auteurs déclarent n’avoir aucun lien d’intérêt en rapport avec cet article.

Myelodysplastic syndromes (MDS) are clonal myeloid haemopathies mainly affecting elderly subjects. The recently updated international classifications of the World Health Organisation and the International Consensus Classification now distinguish MDS on the basis of cytological abnormalities (excess blasts) and their genetic profile. Prognostic stratification of patients is essential to guide therapeutic management, the aim of which is to improve symptoms and quality of life in patients with low-risk MDS, or to slow leukaemic transformation in high-risk patients. Therapeutic options have evolved in recent years, with the appearance of new compounds that have obtained marketing authorisation (luspatercept), and other promising targeted therapies (isocitrate dehydrogenase inhibitor, venetoclax), the development of which has been based on a better understanding of the biology of MDS.